bronchodilator

(redirected from Bronchodilators)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

bronchodilator

[¦bräŋ·kō′dī‚lād·ər]
(medicine)
An instrument used to increase the caliber of the pulmonary air passages.
(pharmacology)
Any agent that causes a widening of the air passages in bronchi and bronchioles.
References in periodicals archive ?
If additional adrenergic drugs, including other short-acting sympathomimetic bronchodilators or epinephrine, are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.
further highlights significant bronchodilator and anti-inflammatory
The acquisition includes Elevation Pharmaceuticals EP-101 product, an inhalation solution of a long-acting muscarinic antagonist (LAMA) bronchodilator that is in Phase 2b clinical trials for the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).
today announced the completion of the Company's randomized, double-blind, dose-ranging Phase 2b trial of PT003, Pearl's lead investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD.
RPL554 is a novel long acting bronchodilator and anti-inflammatory drug that acts by simultaneously inhibiting both phosphodiesterase (PDE) 3 and 4.
Ultibro Breezhaler 110/50 mcg is a once-daily LABA/LAMA+ dual bronchodilator approved in the European Union (EU) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
The primary objective of this study is to evaluate whether RPL554 has an additive bronchodilator effect and is well tolerated in COPD patients, when administered in addition to standard of care bronchodilators.
Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
gt;Controllers include inhaled corticosteroids alone or in combination with long-acting bronchodilators.
There are no metered-dose inhaler bronchodilators currently available as OTC products in the United States.
The first, an analysis conducted with data from the National Birth Defects Prevention Study focused specifically on orofacial clefts as the outcome and bronchodilators as the exposure.
We have identified compounds that are more potent than our previously identified set of compounds, paving the way for development of bronchodilators for treating asthma and COPD," said study author Kathryn Robinett, pulmonary and critical care fellow at the University of Maryland School of Medicine.